Library

feed icon rss

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
  • 1
    Electronic Resource
    Electronic Resource
    Springer
    Journal of molecular medicine 63 (1985), S. 740-746 
    ISSN: 1432-1440
    Keywords: Growth factors ; Oncogens ; Clinical application ; Clinical trials
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Summary The current understanding in biology and function of 4 growth factors is reviewed. PDGF suggests functions for proto-oncogens in normal cells, which may interact in tightly linked hierachies to induce malignant growth. PDGF-requirement of normal fibroblast cell-lines is lost when the cells are infected with tumor viruses. TGF is able to stimulate growth of normally anchorage dependent cells in an anchorage independent manner in soft agar. This ability is thought to be the best in-vitro correlate of neoplastic transformation. The peptide hormones bombesin/gastrin releasing factor and EGF can act as autocrine growth factors in various lung cancer cell-lines and stimulate clonal tumor cell growth in-vitro. The potential clinical application of these types of growth factors may enable the in-vitro growth from any lung cancer patient and allow individual drug testing. TCGF produced by T-cells to activate T-cells, is central to immune stimulation and immune response. Models for potential indirect anticancer effects either by in-vivo administration or by in-vivo incubation plus passive transfer of T-cells are presented to be initiated in future clinical trials.
    Type of Medium: Electronic Resource
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 2
    Electronic Resource
    Electronic Resource
    Amsterdam : Elsevier
    Journal of Chromatography B: Biomedical Sciences and Applications 345 (1985), S. 145-149 
    ISSN: 0378-4347
    Source: Elsevier Journal Backfiles on ScienceDirect 1907 - 2002
    Topics: Chemistry and Pharmacology
    Type of Medium: Electronic Resource
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 3
    Electronic Resource
    Electronic Resource
    Amsterdam : Elsevier
    Bioelectrochemistry and Bioenergetics 23 (1990), S. 285-299 
    ISSN: 0302-4598
    Source: Elsevier Journal Backfiles on ScienceDirect 1907 - 2002
    Topics: Biology , Chemistry and Pharmacology , Physics
    Type of Medium: Electronic Resource
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 4
    Electronic Resource
    Electronic Resource
    Amsterdam : Elsevier
    Nuclear Inst. and Methods in Physics Research, B 33 (1988), S. 49-52 
    ISSN: 0168-583X
    Source: Elsevier Journal Backfiles on ScienceDirect 1907 - 2002
    Topics: Physics
    Type of Medium: Electronic Resource
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 5
    Electronic Resource
    Electronic Resource
    Springer
    Der Internist 41 (2000), S. 544-552 
    ISSN: 1432-1289
    Keywords: Schlüsselwörter Alter ; Maligne Erkrankungen ; Zytostatische Chemotherapie ; Palliative Therapie ; Geriatrische Onkologie
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Zum Thema Die Zunahme maligner Erkrankungen und der durch sie bedingten Todesfälle ist entscheidend durch die Zunahme der allgemeinen Lebenserwartung und das mit dem Lebensalter steigende Risiko einer Krebserkrankung bedingt. Die Häufigkeit von Begleiterkrankungen und Einschränkungen der Organfunktionen nimmt mit steigendem Lebensalter zu. Dieser Beitrag beschreibt wichtige Gesichtspunkte, in denen daher die Therapie maligner Erkrankungen im höheren Lebensalter anders einzuschätzen ist als bei jüngeren Patienten. So ist auch die Abwägung zwischen Lebensverlängerung und Lebensqualität eine wichtige Frage, die sich im Alter besonders stellt.
    Type of Medium: Electronic Resource
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 6
    ISSN: 1432-2102
    Keywords: Schlüsselwörter Katheterisierung ; Port-Katheter-Systeme ; i.v. Chemotherapie ; Interventionelle Radiologie ; Key words Indwelling catheters ; Port-catheter systems ; Intravenous chemotherapy ; Interventional radiologic techniques
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Description / Table of Contents: Summary Purpose: Percutaneous interventional radiologic and surgical techniques of port-catheter implantation are described and compared with regard to the technical procedure and results. Materials and methods: In 53 patients with various malignancies interventional radiologic implantation of port-catheter systems into the subclavian vein was performed to provide long-term intravenous access for chemotherapy. The technical procedure, operation time, complication rates and long-term patency were compared with those of surgically implanted systems. Results: Implantation was successful in all cases. Mean operation time was 36 min (range 20–55 min). Mean function time was 189 days (range 7–518). Primary patency rate was 92.5% with a total complication rate of 15% (8/53). In three patients (5.7%) pneumothorax was observed but did not require further treatment. In two cases (3.8%) local infection occurred, and in one patient (1.8%) a non-complicated wound dehiscence. In 12/53 patients (22.6%) the system was withdrawn. Among these, withdrawal was due to complications in 4/53 (7.6%) cases. Conclusions: Interventional radiologic implantation of long-term intravenous port-catheter systems is comparable to surgical placement with regard to both complication rate and long-term patency.
    Notes: Zusammenfassung Fragestellung: Die perkutane interventionellradiologische und die chirurgische Implantation von venösen Port-Katheter-Systemen werden beschrieben und ihre Ergebnisse werden vergleichend gegenübergestellt. Methode: Bei 53 Patienten mit maligner Grunderkrankung wurde interventionell-radiologisch ein Port-Katheter-System in der V. subclavia zur zentralvenösen Chemotherapie implantiert. Technisches Vorgehen, Implantationsdauer, Funktionsdauer sowie die Komplikationsraten wurden mit Ergebnissen der chirurgischen Implantation verglichen. Ergebnisse: Die Implantation war in allen Fällen erfolgreich. Die mittlere Dauer der Maßnahme betrug 36 min (20–55 min), die mittlere Funktionsdauer der Systeme 189 Tage (7–518 Tage). Die Funktionsrate betrug 92,5% bei einer Komplikationsrate von 15% (8/53). In 3 Fällen (5,7%) trat ein Pneumothorax auf, in 2 Fällen (3,8%) eine Infektion, in 2 weiteren Fällen eine Okklusion bzw. ein Katheterdefekt und in 1 Fall (1,8%) eine unkomplizierte Wunddehiszenz. Bei 12/53 Patienten (22,6%) wurde das Port-Katheter-System explantiert, davon in 4 Fällen (7,6%) komplikationsbedingt. Schlußfolgerungen: Die interventionell-radiologische Implantation von zentralvenösen Langzeit-Port-Katheter-Systemen ist in Technik und Komplikationsrate der chirurgischen Methode vergleichbar.
    Type of Medium: Electronic Resource
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 7
    Electronic Resource
    Electronic Resource
    Springer
    Annals of hematology 63 (1991), S. 179-188 
    ISSN: 1432-0584
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Summary AML in elderly patients is a heterogeneous disease which is characterized by a number of unfavorable features such as development, cytogenetics, blast cell differentiation, and poor treatment response. Specifically, the association between a higher incidence of unfavorable cytogenetic abnormalities in elderly patients and poor prognosis has been well documented. Low treatment response may be due to the specific biology of AML in this patient group, but also to host-specific factors such as higher treatment-related morbidity and mortality. Treatment tolerance cannot be judged on grounds of chronological age alone; risk factor analysis with regard to performance status, organ function, and underlying systemic disease need to be considered as well. For effective induction treatment in elderly patients, instant and intensive chemotherapy appears to be necessary, while delayed treatment or administration of supportive care alone provide unsatisfactory results. Standard-dose ara-C/anthracycline-containing regimens are the treatment of choice in patients with good performance status. However, patients with a WHO grading of 〉3 might rather benefit from reduced regimens such as low-dose ara-C. At present, greatest improvement of AML treatment in elderly patients can be expected from an improvement of supportive care.
    Type of Medium: Electronic Resource
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 8
    Electronic Resource
    Electronic Resource
    Springer
    Annals of hematology 66 (1993), S. 131-134 
    ISSN: 1432-0584
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Summary Twenty-five consecutive leukemia patients (21 AML, 4 ALL) with either primary resistance (n=22) or resistant relapse (n=3) of all FAB subtypes were treated with 1 or 2 cycles of ID-ara C (1 g/m2 i.v. q 12 h, days 1–6) and AMSA (120 mg/m2 i.v., days 5–7). Patients reaching CR received 1 cycle of intensive consolidation using ara C 3 g/m2 i.v. q 12 h, days 1–4 and AMSA 120 mg/m2 i.v., day 5. Two patients received an allograft thereafter and are still alive and in CCR. CR was achieved in 12/25 patients (48%), ten after 1 cycle of induction and two after 2 cycles; 10/22 patients with primary resistant disease reached CR, and 2/3 with resistant relapse. Nine patients remained refractory (36%) and four died during hypoplasia (16%). Median DFS of the 12 responders was 2.9 months, median survival from time of CR 8.9 months. Median overall survival of responders and nonresponders was 6 months from time of resistance. Survival advantage of responding patients (n=12) as compared with nonresponders (n=13) was 10.7 vs 3.2 months (p=0.002). Toxicity of chemotherapy was acceptable: one patient experienced pulmonary edema due to ara C; two patients developed life-threatening systemic fungal infections, one of whom died while in CR.
    Type of Medium: Electronic Resource
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 9
    ISSN: 1432-0584
    Keywords: Aspergillosis ; Amphotericin B Inhalation ; Neutropenia ; Prophylaxis
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Abstract To determine the value of aerosol amphotericin B inhalations for prevention of invasive pulmonary aspergillosis (IPA), we initiated a prospective randomized multicenter trial. The scheduled intent-to-treat interim analysis included 115 patients (30%) with prolonged neutropenia after chemotherapy for acute myeloid leukemia, acute lymphoblastic leukemia/high-grade non-Hodgkin's lymphoma, or solid tumors undergoing autologous stem cell transplantation. Sixty-five patients had been randomized to receive prophylactic aerosol amphotericin B inhalations at a dose of 10 mg twice daily (group A); for the remaining 50 patients no aerosol amphotericin B prophylaxis was used (group B). No serious side effects from amphotericin B inhalations occurred, but coughing (54%), bad taste (51%), and nausea (37%) caused early cessation of aerosol amphotericin B prophylaxis in 23% (15/65) of courses. In group A, the incidence of proven, probable, or possible IPA was 5% (3/65) as compared with 12% (6/50) in group B (p〉0.05). Microbiologically documented bacterial pneumonias were observed in 5/65 (8%) patients in group A and in 1/50 (2%) patients in group B (p〉0.05). Thus, no reduction in incidence of IPA from use of prophylactic aerosol amphotericin B inhalations was found in this interim analysis. As there were no serious side effects from aerosol amphotericin B prophylaxis, accrual in the study will continue for a total of 380 patients.
    Type of Medium: Electronic Resource
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 10
    Electronic Resource
    Electronic Resource
    Springer
    Annals of hematology 64 (1992), S. 157-159 
    ISSN: 1432-0584
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Conclusion Both normal and leukemic myeloid clones are apparently characterized in the elderly by the same two biological features: (a) Increased cell proliferation [2, 13, 15] and (b) decreased cell differentiation [4, 5, 7, 12], which consequently have serious therapeutic implications for elderly AML patients. Low-dose cytarabine therapy has several advantages over conventional intensive chemotherapy in elderly AML patients, including: 1. The early death rate is significantly lower [18]. 2. Remission induction rates (complete + long lasting partial remissions) [18] are comparable. 3. Survival duration rates [18] are comparable. 4. Low-dose cytarabine not only decreases the cell proliferation of normal and leukemic myeloid clones as conventional intensive chemotherapy does; it also increases the cell differentiation of both normal [3] and leukemic [1, 11, 14, 17] myeloid clones. 5. Low-dose cytarabine therapy could be effective after the failure of conventional intensive chemotherapy in AML patients [16].
    Type of Medium: Electronic Resource
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...